8-K: Hinge Health Reports Record Q4, Full Year 2025 Results

Hinge Health announced record financial results for the fourth quarter and full year 2025, driven by strong commercial momentum and expanding margins.

Summary

• Revenue for Q4 2025 increased 46% year-over-year to $170.7 million, compared to $117.3 million in Q4 2024.
• Full year 2025 revenue grew 51% year-over-year to $587.9 million, up from $390.4 million in 2024.
• Non-GAAP income from operations for Q4 2025 surged 124% to $48.0 million, and for the full year 2025, it reached $119.5 million, a significant improvement from a non-GAAP loss of $26.1 million in 2024.
• Net cash provided by operating activities for the full year 2025 increased 250% to $171.4 million, compared to $49.0 million in 2024.
• Free cash flow for the full year 2025 increased 297% to $179.6 million, up from $45.2 million in 2024.
• The company's Rule of 40 metric improved to 81 in 2025 from 45 in 2024, measured by revenue growth plus free cash flow margin.
• The number of clients increased 25% year-over-year to 2,830, and contracted lives grew to 25 million as of December 31, 2025.
• Hinge Health repurchased $65.0 million in aggregate value of its Class A common stock in Q4 2025 under a $250.0 million authorized program.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, driven by exceptional revenue growth, strong non-GAAP profitability, robust cash generation, and significant operational expansion, despite the GAAP loss primarily due to non-cash stock-based compensation.

Positives

• Record revenue growth: Q4 2025 revenue increased 46% to $170.7 million, and Full Year 2025 revenue increased 51% to $587.9 million.
• Significant improvement in non-GAAP profitability: Q4 2025 non-GAAP income from operations surged 124% to $48.0 million, and Full Year 2025 non-GAAP income from operations reached $119.5 million, reversing a loss from 2024.
• Strong cash generation: Full Year 2025 net cash provided by operating activities increased 250% to $171.4 million, and free cash flow increased 297% to $179.6 million.
• Expanding gross margins: GAAP gross margin improved to 84% in Q4 2025 (from 82%) and 80% for Full Year 2025 (from 77%). Non-GAAP gross margin also improved.
• Robust client and member growth: Clients increased 25% to 2,830; contracted lives grew to 25 million; members increased 47% to 782,890.
• Improved efficiency: The Rule of 40 metric rose significantly to 81 in 2025 from 45 in 2024.
• Shareholder return: Repurchased $65.0 million of Class A common stock in Q4 2025 as part of a $250.0 million authorized program.
• Positive future outlook: Q1 2026 revenue guidance of $171M-$173M (39% YoY growth) and Full Year 2026 revenue guidance of $732M-$742M (25% YoY growth) with expanding non-GAAP operating margins.

Negatives

• Reported a significant GAAP loss from operations for the full year 2025 of $(546.4) million, a substantial increase from a GAAP loss of $(31.9) million in 2024, primarily due to high stock-based compensation expense.
• GAAP net loss for the full year 2025 was $(528.261) million.

Risks

• Actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from projections, as more fully described in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and its Annual Report on Form 10-K for the year ended December 31, 2025, when filed.

Future Outlook

Hinge Health expects Q1 2026 revenue to be between $171 million and $173 million, representing 39% year-over-year growth at the midpoint, with non-GAAP income from operations projected between $30 million and $32 million. For the full year 2026, revenue is anticipated to be between $732 million and $742 million, reflecting 25% year-over-year growth at the midpoint, and non-GAAP income from operations is guided to be between $151 million and $156 million, indicating 29% year-over-year growth and a 21% non-GAAP operating margin at the midpoint.

Management Comments

• "We closed out the year with an exceptional quarter and a strong selling season, driving our highest win rates to date and greatest number of eligible lives added in any year."
• "Our commercial momentum, combined with expanding margins and strong cash generation, gives us confidence in our ability to continue automating care delivery, sustain our position as a leader in digital musculoskeletal care, and drive attractive growth and increased margins in 2026."

Industry Context

StockSavvy.ai notes that Hinge Health's strong performance, particularly in client and member growth and the Rule of 40 metric, indicates robust demand for digital musculoskeletal care solutions. The company's focus on automating care delivery and leveraging AI-powered technology aligns with broader healthcare trends towards efficiency, personalization, and virtual care, positioning it well within a competitive and evolving market.

Comparison to Industry Standards

• StockSavvy.ai observes Hinge Health's Rule of 40 metric of 81 in 2025 significantly surpasses the industry benchmark of 40 for SaaS and high-growth technology companies, indicating exceptional efficiency in balancing growth and profitability.
• The 51% year-over-year revenue growth for 2025 positions Hinge Health as a high-growth leader in the digital health sector, outperforming many established healthcare technology firms that typically see growth rates in the 15-30% range.
• The substantial increase in free cash flow by 297% to $179.6 million for 2025 demonstrates superior cash generation capabilities compared to many digital health startups that often prioritize growth over immediate cash flow.

Stakeholder Impact

• Shareholders: Highly positive due to strong financial performance, significant cash generation, positive future outlook, and a share repurchase program indicating confidence in valuation and commitment to shareholder returns.
• Employees: Positive due to company growth and the significant stock-based compensation, though the GAAP loss might obscure underlying operational profitability for some.
• Customers (Clients): Positive as the company's commercial momentum and expanding margins suggest continued investment in platform development and service delivery, improving member outcomes and experiences.
• Creditors: Positive due to strong cash position ($478.8 million in cash, equivalents, and marketable securities) and robust cash flow from operations, indicating strong ability to meet financial obligations.

Next Steps

• Host a conference call and webcast on February 10, 2026, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial results, business highlights, and financial outlook.
• Continue automating care delivery and sustaining leadership in digital musculoskeletal care.
• Drive attractive growth and increased margins in 2026.
• File Annual Report on Form 10-K for the year ended December 31, 2025, with the SEC.

Key Dates

Recommendation

The filing demonstrates exceptional financial and operational performance, including robust revenue growth, a significant turnaround to non-GAAP operating profitability, and substantial free cash flow generation. The company's key metrics, such as client and member growth, and the Rule of 40, are highly impressive. The positive guidance for 2026 and the active share repurchase program further underscore management's confidence and commitment to shareholder value. While a large GAAP loss exists, it is primarily due to non-cash stock-based compensation, which is common in high-growth tech companies and less indicative of core operational health than the non-GAAP metrics and cash flow. These factors collectively point to a strong investment opportunity.

Keywords

Hinge Health, HNGE, financial results, Q4 2025, full year 2025, earnings, revenue, digital musculoskeletal care, healthcare technology, cash flow, stock repurchase, guidance, non-GAAP, operating income, client growth, member growth, Rule of 40